pracinostat-sb939

Description: Pracinostat (formerly SB-939) is a novel, potent and orally bioavailable pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity. It exhibits relatively higher selectivity (more than 1000-fold) for class I, class II and class IV HDACs rather than class III HDACs. It shows potent anti-proliferative activity in vitro against a wide range of cancer cell lines, including colon cancer, ovarian cancer, prostate carcinomas, acute myeloid leukaemia (AML) and B cell lymphoma. As of March 2014, pracinostat has been granted by FDA Orphan Drug status for the treatment of acute myelocytic leukemia (AML) and T-cell lymphoma.

References: Mol Cancer Ther. 2010 Mar; 9(3):642-52; Br J Cancer. 2011 Mar 1; 104(5):756-62.

Related CAS: 929016-97-7 (TFA), 929016-96-6 (free base), 929016-98-8 (2HCl)

Chemical Name: (E)-3-(2-butyl-1-(2-(diethylamino)ethyl)-1H-benzo[d]imidazol-5-yl)-N-hydroxyacrylamide

InChi Key: JHDKZFFAIZKUCU-ZRDIBKRKSA-N

InChi Code: InChI=1S/C20H30N4O2/c1-4-7-8-19-21-17-15-16(10-12-20(25)22-26)9-11-18(17)24(19)14-13-23(5-2)6-3/h9-12, 15, 26H, 4-8, 13-14H2, 1-3H3, (H, 22, 25)/b12-10+

SMILES Code: O=C(NO)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1